Clinical Trials Browser

Has results × Has announcements × Nivolumab × Clear all

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT03143153 2026-02-17

CheckMate 648

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02998528 2026-01-06

CheckMate 816

Phase 3 Completed

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01658878 2025-12-24

CheckMate040

Phase 1/2 Completed

657 enrolled 57 charts 3 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT03215706 2025-12-17

CheckMate 9LA

Phase 3 Completed

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02743494 2025-11-18

CheckMate 577

Phase 3 Completed

794 enrolled 13 charts 1 FDA

Advanced Cancer

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT02632409 2025-10-16

CheckMate 274

Phase 3 Active not recruiting

709 enrolled 13 charts 1 FDA

Various Advanced Cancer

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Phase 3 Active not recruiting

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04008030 2025-10-03

CheckMate 8HW

Phase 3 Active not recruiting

839 enrolled 22 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Melanoma, Neoplasms

NCT04099251 2025-08-27

CheckMate76K

Phase 3 Active not recruiting

790 enrolled 18 charts 1 FDA

Melanoma

NCT02872116 2025-08-07

CheckMate649

Phase 3 Completed

2,031 enrolled 19 charts 1 FDA

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT02388906 2025-04-24

CheckMate 238

Phase 3 Completed

906 enrolled 16 charts 1 FDA

Melanoma

NCT01928394 2024-12-27

A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors

Phase 1/2 Completed

1,163 enrolled 33 charts 1 FDA

Other solid neoplasm

Advanced or Metastatic Solid Tumors

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Completed

419 enrolled 20 charts 2 FDA

Gastrointestinal

Esophageal Neoplasms